$ATNX News

Last published 3y ago

3y agoATNXAthenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales ProcessGlobeNewswireTo Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May
3y agoATNXQuantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCOPR NewswireSAN FRANCISCO, May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (NASDAQ:ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex's oral paclitaxel
3y agoATNXAthenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business UpdateGlobeNewswireExploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or
3y agoATNXAthenex Announces a Reverse Stock SplitGlobeNewswireBUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of
3y agoATNXAthenex Announces MHRA Decision on Oral PaclitaxelGlobeNewswireMHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel The MHRA
3y agoATNXAthenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast CancerGlobeNewswireBUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of
3y agoATNXAthenex Exits 503B Sterile Compounding BusinessGlobeNewswireBUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of
3y agoATNXAthenex Announces Positive Results of Special Stockholder MeetingGlobeNewswireShareholders voted in favor of all three proposals submitted before the Special Stockholder Meeting BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company
3y agoATNXAthenex Announces Closing of the Sale of its China API BusinessGlobeNewswireBUFFALO, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of
4y agoATNXAthenex to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireBUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer
4y agoATNXAthenex Announces Receipt of Positive Nasdaq Listing DeterminationGlobeNewswireBUFFALO, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of
4y agoATNXAthenex Provides Third Quarter 2022 Financial Results and Business UpdateGlobeNewswireBolstered balance sheet with $30 million public offering of common stock and warrantsNasdaq Hearing Panel grants Athenex's request for continued listingAthenex is in the final stages of closing the sale of the China API
4y agoATNXAthenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022GlobeNewswireBUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer
4y agoATNXAthenex Files Definitive Proxy Statement for Special Stockholder MeetingGlobeNewswireSpecial Stockholder Meeting will be held as a virtual meeting on November 22, 2022 at 9:30 a.m. Eastern Time BUFFALO, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical
4y agoATNXAthenex to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireBUFFALO, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today an
4y agoATNXAthenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and WarrantsGlobeNewswireBUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. ("Athenex") (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related cond
4y agoATNXAthenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and WarrantsGlobeNewswireBUFFALO, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. ("Athenex") (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related cond
4y agoATNXAthenex Provides Second Quarter 2022 Financial Results and Business UpdateGlobeNewswireReports 2Q product sales of $25.8 million, up 26% year-over-year Raised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 mi
4y agoATNXAthenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical OncologyGlobeNewswireBUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, toda
4y agoATNXAthenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022GlobeNewswireBUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today annou
4y agoATNXAthenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.GlobeNewswireExpected sale proceeds of approximately $19.0 million Company continues to monetize non-core assets to extend cash runway Proceeds from the deal will be used to pay down debt and fund operations BUFFALO, N.Y., July 11, 2022 (GLOBE NEWSWIRE)
4y agoATNXAthenex to Participate in Truist Securities Cell Therapy SymposiumGlobeNewswireBUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today annou
4y agoATNXAthenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and OaktreeGlobeNewswireCompany executes on strategy to extend cash runway by monetizing non-core assets Total transaction value of $85 million; at least $80 million to be used toward debt paydown and to fund operations BUFFALO, N.Y., June 22, 2022 (GLOBE NEWSWIRE)
4y agoATNXAthenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell TherapyGlobeNewswireBUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, toda
4y agoATNXAthenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)GlobeNewswireBUFFALO, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today
4y agoATNXAthenex Provides First Quarter 2022 Financial Results and Business UpdateGlobeNewswireReports 1Q product sales of $29.0M, up 42% year-over-year Encouraging interim update from ANCHOR study of KUR-502 presented at ASTCT with 60% overall response rate (ORR) and 6-month complete response (CR) rate of 29% in the NHL cohort Abstract for KU
4y agoATNXAthenex, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASGCT 25th Annual MeetingGlobeNewswireData presented by investigators from the Texas Children's Cancer Center's Center for Advanced Innate Cell Therapy and Baylor College of Medicine Data demonstrate expansion of CAR-NKT cells post-transfer in all patients, and objective responses in pati
4y agoATNXAthenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular ("Tandem") Meetings of ASTCT and CIBMTRGlobeNewswireInterim analysis provides response data from 7 evaluable patients including two additional patients, one with non-Hodgkin lymphoma (NHL) and one with acute lymphoblastic leukemia (ALL) Six-month CR rate of 29%, including 1 ongoing CR at 34 weeks in he
4y agoATNXAthenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswireAnnounces Strategic Pivot to Focus on Cell Therapy Programs Receives FDA Clearance for IND to Expand CD19 CAR-NKT ANCHOR to a Multi-center Study Implementing Significant Cost Reduction Plan Targeting >50% Reduction in Operating Expenses Pl
4y agoATNXCORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022GlobeNewswireBUFFALO, N.Y., March 14, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today anno
4y agoATNXAthenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022GlobeNewswireBUFFALO, N.Y., March 07, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today anno
4y agoATNXAthenex Announces Appointment of Chief Financial OfficerGlobeNewswireBUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, anno
4y agoATNX IBRXAthenex Announces Completion of Sale of Dunkirk Manufacturing FacilityGlobeNewswireBUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, anno
4y agoATNX IBRXImmunityBio Completes Acquisition of Athenex's Interest in Dunkirk, New York Advanced Biotech Manufacturing FacilityBusiness Wire409,000 square foot, state-of-the-art facility expands capabilities for large-scale manufacture of vaccine and immunotherapy product candidates ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company ("ImmunityBio"), today announced t
4y agoATNXAthenex to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireBUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, toda
4y agoATNX IBRXAthenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing FacilityGlobeNewswireBUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, ann
4y agoATNX IBRXImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and PreparednessBusiness WireOver 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing Practices (cGMP) facility with clean rooms will exped
4y agoATNXAthenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual MeetingGlobeNewswireThe Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform Interim results from five evaluable patients in ANCHOR study of KUR-502 showed 80% Overall Response Rate and 60% Complete Respo
4y agoATNXAthenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to CancerGlobeNewswirePresentations Will Include a Review of ANCHOR Study Data on KUR-502 from ASH Annual Meeting Webinar on Monday, December 13th, at 9:00 a.m. ET BUFFALO, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutica
4y agoATNXAthenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for ReviewGlobeNewswireBUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, anno
4y agoATNXAthenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021GlobeNewswireAnalysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities Post hoc analysis of this subgroup of patients with hepatic impairment was conducted and showed a median survival rat
4y agoATNXAthenex to Present at the Evercore ISI 4th Annual HealthCONx ConferenceGlobeNewswireBUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, toda
5y agoATNXAthenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell TherapiesGlobeNewswireBUFFALO, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today annou
5y agoATNXAthenex, inc (ATNX) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsATNX earnings call for the period ending September 30, 2021.
5y agoATNXAthenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and ExpositionGlobeNewswireResults from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR). Updated data show continued favorable safety profile and encouraging anti-tumo
5y agoATNXAthenex Provides Third Quarter 2021 Corporate and Financial UpdateGlobeNewswireHeld FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M, up 9% year-over-year Company now ex
5y agoATNXAthenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021GlobeNewswireBUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today annou
5y agoATNXAthenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021GlobeNewswireBUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today annou
5y agoATNXAthenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell TherapyGlobeNewswirePatent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) Patent protection helps validate the groundbreaking innovation of
5y agoATNX FCEL LCID SLI+1Thinking about buying stock in Protara Therapeutics, Standard Lithium, Lucid Group, Athenex, or FuelCell Energy?PR NewswireNEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TARA, SLI, LCID, ATNX, and FCEL.